|also spelled hemophilia|
Deficiency in coagulation factor VIII is the most common cause of haemophilia.
|Classification and external resources|
|OMIM||306700 306900 264900|
Haemophilia is a mostly inherited, genetic disorder that impairs the body's ability to form blood clots, a process needed to stop bleeding when a blood vessel is broken. There are two main types, haemophilia A and haemophilia B. Haemophilia A is due to a deficiency in clotting factor VIII and is the most common type, present in about 1 in 5,000–10,000 male births. Haemophilia B is due to a deficiency in factor IX and occurs in around 1 in about 20,000–34,000 male births. A third type haemophilia C due to a deficiency in factor XI, is a rare, mild form that can affect both sexes. This type is mostly found in Ashkenazy Jews  and rarely in other population groups.
Another mild and rare form of haemophilia is known as parahaemophilia and is due to a deficiency in factor V, which can be inherited or acquired. A non-genetic form of haemophilia is caused by autoantibodies against factor VIII and so is known as acquired haemophilia A. Acquired haemophilia can be associated with cancers, autoimmune disorders and following childbirth.
Like other X-linked recessive disorders, haemophilia A and B are more likely to occur in males than females. This is because females have two X chromosomes while males have only one, so the defective gene is guaranteed to manifest in any male who carries it. Because females have two X chromosomes and haemophilia is rare, the chance of a female having two defective copies of the gene is very remote, so females are almost exclusively asymptomatic carriers of the disorder. Female carriers can inherit the defective gene from either their mother or father, or it may be a new mutation. Although it is not impossible for a female to have haemophilia, it is unusual: daughters which are the product of both a male with haemophilia A or B and a female carrier will possess a 50% chance of having haemophilia.
People with haemophilia have lower clotting factor level of blood plasma or impaired activity of the coagulation factors needed for a normal clotting process. Thus when a blood vessel is injured, a temporary scab does form, but the missing coagulation factors prevent fibrin formation, which is necessary to maintain the blood clot. A haemophiliac does not bleed more intensely than a person without it, but can bleed for a much longer time. In severe cases even a minor injury can result in blood loss lasting days or weeks, or even never healing completely. In areas such as the brain or inside joints, this can be fatal or permanently debilitating. The word is from the Greek haima αἷμα 'blood' and philia φιλία 'love'.
- 1 Signs and symptoms
- 2 Genetics
- 3 Diagnosis
- 4 Management
- 5 Prognosis
- 6 Epidemiology
- 7 History
- 8 See also
- 9 References
- 10 External links
Signs and symptoms
Characteristic symptoms vary with severity. In general symptoms are internal or external bleeding episodes, which are called "bleeds". People with more severe haemophilia suffer more severe and more frequent bleeds, while people with mild haemophilia usually suffer more minor symptoms except after surgery or serious trauma. In cases of moderate haemophilia symptoms are variable which manifest along a spectrum between severe and mild forms.
In both haemophilia A and B, there is spontaneous bleeding but a normal bleeding time, normal prothrombin time, normal thrombin time, but prolonged partial thromboplastin time. Internal bleeding is common in people with severe haemophilia and some individuals with moderate haemophilia. The most characteristic type of internal bleed is a joint bleed where blood enters into the joint spaces. This is most common with severe haemophiliacs and can occur spontaneously (without evident trauma). If not treated promptly, joint bleeds can lead to permanent joint damage and disfigurement. Bleeding into soft tissues such as muscles and subcutaneous tissues is less severe but can lead to damage and requires treatment.
Children with mild to moderate haemophilia may not have any signs or symptoms at birth especially if they do not undergo circumcision. Their first symptoms are often frequent and large bruises and haematomas from frequent bumps and falls as they learn to walk. Swelling and bruising from bleeding in the joints, soft tissue, and muscles may also occur. Children with mild haemophilia may not have noticeable symptoms for many years. Often, the first sign in very mild haemophiliacs is heavy bleeding from a dental procedure, an accident, or surgery. Females who are carriers usually have enough clotting factors from their one normal gene to prevent serious bleeding problems, though some may present as mild haemophiliacs.
Severe complications are much more common in cases of severe and moderate haemophilia. Complications may arise from the disease itself or from its treatment:
- Deep internal bleeding, e.g. deep-muscle bleeding, leading to swelling, numbness or pain of a limb.
- Joint damage from haemarthrosis (haemophilic arthropathy), potentially with severe pain, disfigurement, and even destruction of the joint and development of debilitating arthritis.
- Transfusion transmitted infection from blood transfusions that are given as treatment.
- Adverse reactions to clotting factor treatment, including the development of an immune inhibitor which renders factor replacement less effective.
- Intracranial haemorrhage is a serious medical emergency caused by the buildup of pressure inside the skull. It can cause disorientation, nausea, loss of consciousness, brain damage, and death.
Haemophilic arthropathy is characterized by chronic proliferative synovitis and cartilage destruction. If an intra-articular bleed is not drained early, it may cause apoptosis of chondrocytes and affect the synthesis of proteoglycans. The hypertrophied and fragile synovial lining while attempting to eliminate excessive blood may be more likely to easily rebleed, leading to a vicious cycle of hemarthrosis-synovitis-hemarthrosis. In addition, iron deposition in the synovium may induce an inflammatory response activating the immune system and stimulating angiogenesis, resulting in cartilage and bone destruction.
|This section does not cite any sources. (April 2013) (Learn how and when to remove this template message)|
Females possess two X-chromosomes, males have one X and one Y-chromosome. Since the mutations causing the disease are X-linked recessive, a female carrying the defect on one of her X-chromosomes may not be affected by it, as the equivalent allele on her other chromosome should express itself to produce the necessary clotting factors, due to X inactivation. However, the Y-chromosome in the male has no gene for factors VIII or IX. If the genes responsible for production of factor VIII or factor IX present on a male's X-chromosome are deficient there is no equivalent on the Y-chromosome to cancel it out, so the deficient gene is not masked and the disorder will develop.
Since a male receives his single X-chromosome from his mother, the son of a healthy female silently carrying the deficient gene will have a 50% chance of inheriting that gene from her and with it the disease; and if his mother is affected with haemophilia, he will have a 100% chance of being a haemophiliac. In contrast, for a female to inherit the disease, she must receive two deficient X-chromosomes, one from her mother and the other from her father (who must therefore be a haemophiliac himself). Hence haemophilia is far more common among males than females. However, it is possible for female carriers to become mild haemophiliacs due to lyonisation (inactivation) of the X-chromosomes. Haemophiliac daughters are more common than they once were, as improved treatments for the disease have allowed more haemophiliac males to survive to adulthood and become parents. Adult females may experience menorrhagia (heavy periods) due to the bleeding tendency. The pattern of inheritance is criss-cross type. This type of pattern is also seen in colour blindness.
A mother who is a carrier has a 50% chance of passing the faulty X-chromosome to her daughter, while an affected father will always pass on the affected gene to his daughters. A son cannot inherit the defective gene from his father. This is a recessive trait and can be passed on if cases are more severe with carrier.Genetic testing and genetic counselling is recommended for families with haemophilia. Prenatal testing, such as amniocentesis, is available to pregnant women who may be carriers of the condition.
As with all genetic disorders, it is of course also possible for a human to acquire it spontaneously through mutation, rather than inheriting it, because of a new mutation in one of their parents' gametes. Spontaneous mutations account for about 33% of all cases of haemophilia A. About 30% of cases of haemophilia B are the result of a spontaneous gene mutation.
If a female gives birth to a haemophiliac son, either the female is a carrier for the blood disorder or the haemophilia was the result of a spontaneous mutation. Until modern direct DNA testing, however, it was impossible to determine if a female with only healthy children was a carrier or not. Generally, the more healthy sons she bore, the higher the probability that she was not a carrier.
If a male is afflicted with the disease and has children with a female who is not even a carrier, his daughters will be carriers of haemophilia. His sons, however, will not be affected with the disease. The disease is X-linked and the father cannot pass haemophilia through the Y-chromosome. Males with the disorder are then no more likely to pass on the gene to their children than carrier females, though all daughters they sire will be carriers and all sons they father will not have haemophilia (unless the mother is a carrier).
There are numerous different mutations which cause each type of haemophilia. Due to differences in changes to the genes involved, people with haemophilia often have some level of active clotting factor. Individuals with less than 1% active factor are classified as having severe haemophilia, those with 1-5% active factor have moderate haemophilia, and those with mild haemophilia have between 5-40% of normal levels of active clotting factor.
|This section does not cite any sources. (April 2016) (Learn how and when to remove this template message)|
Haemophilia A can be mimicked by von Willebrand disease.
- could significantly affect as many as 1 in 10,000 people.
- type 2A, where decreased levels of von Willebrand Factor can lead to premature proteolysis of Factor VIII. In contrast to haemophilia, vWD type 2A is inherited in an autosomal dominant fashion.
- proteolysis of Factor VIII. In contrast to haemophilia, vWD type 3 is inherited in an autosomal recessive fashion.
Additionally, severe cases of vitamin K deficiency can present similar symptoms to haemophilia. This is because vitamin K is necessary for the human body to produce several protein clotting factors. This vitamin deficiency is rare in adults and older children but is common in newborns. Infants are born with naturally low levels of vitamin K and do not yet have the symbiotic gut flora to properly synthesise their own vitamin K. Bleeding issues due to vitamin K deficiency in infants is known as "haemorrhagic disease of the newborn". To avoid this complication, newborns are routinely injected with vitamin K supplements.
Haemophilia A, is a recessive X-linked genetic disorder resulting in a deficiency of functional clotting Factor VIII. Haemophilia B, is aso a recessive X-linked genetic disorder involving a lack of functional clotting Factor IX. Haemophilia C, is an autosomal genetic disorder involving a lack of functional clotting Factor XI.
A non-genetic form of haemophilia is caused by autoantibodies against factor VIII and so is known as acquired haemophilia A. Acquired haemophilia can be associated with cancers, autoimmune disorders and following childbirth.
Though there is no cure for haemophilia, it can be controlled with regular infusions of the deficient clotting factor, i.e. factor VIII in haemophilia A or factor IX in haemophilia B. Factor replacement can be either isolated from human blood serum, recombinant, or a combination of the two. Some haemophiliacs develop antibodies (inhibitors) against the replacement factors given to them, so the amount of the factor has to be increased or non-human replacement products must be given, such as porcine factor VIII.
If a person becomes refractory to replacement coagulation factor as a result of circulating inhibitors, this may be partially overcome with recombinant human factor VII (NovoSeven), which is registered for this indication in many countries.
In early 2008, the US Food and Drug Administration (FDA) approved Xyntha (Wyeth) anti-haemophilic factor, genetically engineered from the genes of Chinese hamster ovary cells. Since 1993 (Dr. Mary Nugent) recombinant factor products (which are typically cultured in Chinese hamster ovary (CHO) tissue culture cells and involve little, if any human plasma products) have been available and have been widely used in wealthier western countries. While recombinant clotting factor products offer higher purity and safety, they are, like concentrate, extremely expensive, and not generally available in the developing world. In many cases, factor products of any sort are difficult to obtain in developing countries.
In Western countries, common standards of care fall into one of two categories: prophylaxis or on-demand. Prophylaxis involves the infusion of clotting factor on a regular schedule in order to keep clotting levels sufficiently high to prevent spontaneous bleeding episodes. On-demand treatment involves treating bleeding episodes once they arise. In 2007, a clinical trial was published in the New England Journal of Medicine comparing on-demand treatment of boys (< 30 months) with haemophilia A with prophylactic treatment (infusions of 25 IU/kg body weight of Factor VIII every other day) in respect to its effect on the prevention of joint-diseases. When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group had a normal index joint-structure on MRI. Prophylactic treatment, however, resulted in average costs of $300,000 per year. The author of an editorial published in the same issue of the NEJM supports the idea that prophylactic treatment not only is more effective than on demand treatment but also suggests that starting after the first serious joint-related haemorrhage may be more cost effective than waiting until the fixed age to begin. This study resulted in the first (October 2008) FDA approval to label any Factor VIII product to be used prophylactically. As a result, the factor product used in the study (Bayer's Kogenate) is now labelled for use to prevent bleeds, making it more likely that insurance carriers in the US will reimburse consumers who are prescribed and use this product prophylactically. Despite Kogenate only recently being "approved" for this use in the US, it and other factor products have been well studied and are often prescribed to treat Haemophilia prophylactically to prevent bleeds, especially joint bleeds.
On 10 December 2011, a team of British and American researchers reported the successful treatment of haemophilia B using gene therapy. The researchers inserted the F9 gene into an adeno-associated virus-8 vector, which has a propensity for the liver, where factor IX is produced, and remains outside the chromosomes so as not to disrupt other genes. The transduced virus was infused intravenously. To prevent rejection, steroids were given to suppress the normal immune response. In October 2013, the Royal Free London NHS Foundation Trust in London reported that after treating six people with haemophilia in early 2011 with the genetically modified adeno-associated virus, over two years later all were still producing blood plasma clotting factor.
It is recommended that people affected with haemophilia do specific exercises to strengthen the joints, particularly the elbows, knees, and ankles. Exercises include elements which increase flexibility, tone, and strength of muscles, increasing their ability to protect joints from damaging bleeds. These exercises are recommended after an internal bleed occurs and on a daily basis to strengthen the muscles and joints to prevent new bleeding problems. Many recommended exercises include standard sports warm-up and training exercises such as stretching of the calves, ankle circles, elbow flexions, and quadriceps sets.
Anticoagulants such as heparin and warfarin are contraindicated for people with haemophilia as these can aggravate clotting difficulties. Also contraindicated are those drugs which have "blood thinning" side effects. For instance, medicines which contain aspirin, ibuprofen, or naproxen sodium should not be taken because they are well known to have the side effect of prolonged bleeding.
Also contraindicated are activities with a high likelihood of trauma, such as motorcycling and skateboarding. Popular sports with very high rates of physical contact and injuries such as American football, hockey, boxing, wrestling, and rugby should be avoided by people with haemophilia. Other active sports like soccer, baseball, and basketball also have a high rate of injuries, but have overall less contact and should be undertaken cautiously and only in consultation with a doctor.
Like most aspects of the disorder, life expectancy varies with severity and adequate treatment. People with severe haemophilia who don't receive adequate, modern treatment have greatly shortened lifespans and often do not reach maturity. Prior to the 1960s when effective treatment became available, average life expectancy was only 11 years. By the 1980s the life span of the average haemophiliac receiving appropriate treatment was 50–60 years. Today with appropriate treatment, males with haemophilia typically have a near normal quality of life with an average lifespan approximately 10 years shorter than an unaffected male.
Since the 1980s the primary leading cause of death of people with severe haemophilia has shifted from haemorrhage to HIV/AIDS acquired through treatment with contaminated blood products. The second leading cause of death related to severe haemophilia complications is intracranial haemorrhage which today accounts for one third of all deaths of people with haemophilia. Two other major causes of death include hepatitis infections causing cirrhosis and obstruction of air or blood flow due to soft tissue haemorrhage.
Haemophilia is rare, with only about 1 instance in every 10,000 births (or 1 in 5,000 male births) for haemophilia A and 1 in 50,000 births for haemophilia B. About 18,000 people in the United States have haemophilia. Each year in the US, about 400 babies are born with the disorder. Haemophilia usually occurs in males and less often in females. It is estimated that about 2500 Canadians have haemophilia A, and about 500 Canadians have haemophilia B.
The first medical professional to describe the disease was Abulcasis. In the tenth century he described families whose males died of bleeding after only minor traumas. While many other such descriptive and practical references to the disease appear throughout historical writings, scientific analysis did not begin until the start of the nineteenth century.
In 1803, Dr. John Conrad Otto, a Philadelphian physician, wrote an account about "a hemorrhagic disposition existing in certain families" in which he called the affected males "bleeders". He recognised that the disorder was hereditary and that it affected mostly males and was passed down by healthy females. His paper was the second paper to describe important characteristics of an X-linked genetic disorder (the first paper being a description of colour blindness by John Dalton who studied his own family). Otto was able to trace the disease back to a woman who settled near Plymouth, NH in 1720. The idea that affected males could pass the trait onto their unaffected daughters was not described until 1813 when John F. Hay, published an account in The New England Journal of Medicine.
In 1924, a Finnish doctor discovered a hereditary bleeding disorder similar to Haemophilia localised in the "Åland Islands", southwest of Finland. This bleeding disorder is called "Von Willebrand Disease".
The term "haemophilia" is derived from the term "haemorrhaphilia" which was used in a description of the condition written by Friedrich Hopff in 1828, while he was a student at the University of Zurich. In 1937, Patek and Taylor, two doctors from Harvard, discovered anti-haemophilic globulin. In 1947, Pavlosky, a doctor from Buenos Aires, found haemophilia A and haemophilia B to be separate diseases by doing a lab test. This test was done by transferring the blood of one haemophiliac to another haemophiliac. The fact that this corrected the clotting problem showed that there was more than one form of haemophilia.
Haemophilia has featured prominently in European royalty and thus is sometimes known as 'the royal disease'. Queen Victoria passed the mutation for Haemophilia B to her son Leopold and, through two of her daughters, Alice and Beatrice, to various royals across the continent, including the royal families of Spain, Germany, and Russia. In Russia, Tsarevich Alexei Nikolaevich, son of Nicholas II, was a descendant of Queen Victoria through his mother Empress Alexandra and suffered from haemophilia.
It was claimed that Rasputin was successful at treating Tsarevich Alexei's haemophilia. At the time, a common treatment administered by professional doctors was to use aspirin, which worsened rather than lessened the problem. It is believed that, by simply advising against the medical treatment, Rasputin could bring visible and significant improvement to the condition of Tsarevich Alexei.
In Spain, Queen Victoria's youngest daughter, Princess Beatrice, had a daughter Victoria Eugenie of Battenberg, who later became Queen of Spain. Two of her sons were haemophiliacs and both died from minor car accidents. Her eldest son, Prince Alfonso of Spain, Prince of Asturias, died at the age of 31 from internal bleeding after his car hit a telephone booth. Her youngest son, Infante Gonzalo, died at age 19 from abdominal bleeding following a minor car accident where he and his sister hit a wall while avoiding a cyclist. Neither appeared injured or sought immediate medical care and Gonzalo died two days later from internal bleeding.
Blood contamination issues
Prior to 1985, there were no laws enacted within the U.S. to screen blood. As a result, many people with haemophilia who received untested and unscreened clotting factor prior to 1992 were at an extreme risk for contracting HIV and hepatitis C via these blood products. It is estimated that more than 50% of the haemophilia population, i.e. over 10,000 people, contracted HIV from the tainted blood supply in the United States alone.
As a direct result of the contamination of the blood supply in the late 1970s and early/mid-1980s with viruses such as hepatitis and HIV, new methods were developed in the production of clotting factor products. The initial response was to heat-treat (pasteurise) plasma-derived factor concentrate, followed by the development of monoclonal factor concentrates, which use a combination of heat treatment and affinity chromatography to inactivate any viral agents in the pooled plasma from which the factor concentrate is derived. The Lindsay Tribunal in Ireland investigated, among other things, the slow adoption of the new methods.
- "Facts | Hemophilia | NCBDDD | CDC". www.cdc.gov. Retrieved 21 June 2016.
- "Hemophilia B". Retrieved 21 November 2007.
- Wynbrandt, James; Ludman, Mark D. (1 January 2009). The Encyclopedia of Genetic Disorders and Birth Defects. Infobase Publishing. pp. 194–. ISBN 978-1-4381-2095-9. Retrieved 25 August 2013.
- Thalji, N; Camire, RM (September 2013). "Parahemophilia: new insights into factor v deficiency.". Seminars in thrombosis and hemostasis 39 (6): 607–12. PMID 23893775.
- Mulliez, SM; Vantilborgh, A; Devreese, KM (June 2014). "Acquired hemophilia: a case report and review of the literature.". International journal of laboratory hematology 36 (3): 398–407. PMID 24750687.
- Franchini, M; Mannucci, PM (December 2013). "Acquired haemophilia A: a 2013 update.". Thrombosis and haemostasis 110 (6): 1114–20. PMID 24008306.
- Douglas Harper. "Online Etymology Dictionary". Retrieved 10 October 2007.
- Types of Bleeds National Hemophilia Federation.
- Key facts: what is haemophilia? The Haemophilia Society.
- Hemophilia Overview eMedicine from webMD. Dimitrios P Agaliotis, MD, PhD, FACP, Robert A Zaiden, MD, Fellow, and Saduman Ozturk, PA-C. Updated: 24 November 2009.
- Hemophilia Complications Mayo Clinic Staff. 16 May 2009
- Rodriguez-Merchan, E. Carlos. "Musculoskeletal Complications of Hemophilia". Retrieved 4 April 2014.
- Valentino LA, Hakobyan N, Rodriguez N, Hoots WK; Kakobyan, N; Rodriguez, N; Hoots, WK (November 2007). "Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage". Haemophilia. 13 Suppl 3: 10–3. doi:10.1111/j.1365-2516.2007.01534.x. PMID 17822515. Retrieved 4 April 2014.
- "What Is Hemophilia? - NHLBI, NIH". www.nhlbi.nih.gov. Retrieved 21 June 2016.
- "Hemophilia A: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2016-06-21.
- Prasad Mathew, MBBS, DCH, eMedicine - Hemophilia C
- "Hemophilia B: MedlinePlus Medical Encyclopedia". www.nlm.nih.gov. Retrieved 2016-06-21.
- Franchini, M; Mannucci, PM (December 2013). "Acquired haemophilia A: a 2013 update.". Thrombosis and haemostasis 110 (6): 1114–20. PMID 24008306.
- Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, Evatt BL (2007). "Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia". N. Engl. J. Med. 357 (6): 535–544. doi:10.1056/NEJMoa067659. PMID 17687129.
- Roosendaal G, Lafeber F (2007). "Prophylactic treatment for prevention of joint disease in hemophilia—cost versus benefit". N. Engl. J. Med. 357 (6): 603–605. doi:10.1056/NEJMe078098. PMID 17687136.
- Kogenate Product Approval Information USDA Center for Biologics Evaluation and Research.
- Hayes, P. 2009. FDA Approves Kogenate For Prophylaxis. Hemaware: the bleeding disorder's magazine. National Hemophilia Foundation. March/April 2009. Vol 14, Issue 2. p. 18.
- Nicholas Wade (10 December 2011). "Treatment for Blood Disease Is Gene Therapy Landmark". The New York Times.
- Geddes, Linda (30 October 2013) 'Bubble kid' success puts gene therapy back on track' The New Scientist, Retrieved 2 November 2013
- (20 November 2014) Gene therapy provides safe, long-term relief for patients with severe hemophilia B Science Daily, Retrieved 17 December 2014
- Mulder, K. 2006. Exercises for People with Hemophilia. World Federation of Hemophilia
- How to Deal with Hemophilia Reviewed by: Larissa Hirsch, MD 2007. kidshealth.org by Nemours. Retrieved 23 January 2010.
- "Playing it Safe: Bleeding Disorders, Sports and Exercise". Booklet. National Hemophilia Foundation.
- World Federation of Hemophilia Frequently Asked Questions. 2005
- World Federation of Hemophilia Frequently Asked Questions About Hemophilia
- "U.S. National Library of Medicine". Retrieved 2 December 2007.
- Canadian Hemophilia Society FAQ
- "Otto JC. The Medical Repository. 1803; Vol VI (1): 1-4". Genmedhist.info. Retrieved 2013-11-21.
- "Case of the Week 175". University of Utah Medical Library. Archived from the original on 19 May 2011.
- Nilsson IM (1994). "Haemophilia--then and now". Sydsvenska medicinhistoriska sallskapets arsskrift 31: 33–52. PMID 11640407.
- DIGITISED EARLY PAPERS AND BOOKS ON HUMAN AND MEDICAL GENETICS Genetics and Medicine Historical Network, Cardiff University.
- Hay J (July 1813). "Account of a remarkable hæmorrhagic disposition, existing in many individuals of the same family". N Engl J Med Surg 2 (3): 221–5. doi:10.1056/NEJM181307010020302.
- "Haemophilia Special Issue: von Willebrand's Disease: a Report from a Meeting in the Åland Islands". Retrieved 22 November 2012.
- "The History of hemophilia". Retrieved 5 June 2009.
- Chapter 38 Coagulation Factors V and VIII by GC White and GE Gilbert in "Blood: principles and practice of hematology: 2nd edition" 2003. Eds. Robert I. Handin, Samuel E. Lux, Thomas P. Stossel. ISBN 978-0-7817-1993-3
- Michael Price (8 October 2009). "Case Closed: Famous Royals Suffered From Hemophilia". ScienceNOW Daily News (AAAS). Retrieved 9 October 2009.
- Evgeny I. Rogaev; et al. (8 October 2009). "Genotype Analysis Identifies the Cause of the "Royal Disease"". Science. Retrieved 9 October 2009.
- In re Rhone-Poulenc Rorer Inc., 51 F.3d 1293, 1296 (7th Cir. 1995), Projectposner.org, Retrieved 28 January 2008
|Wikimedia Commons has media related to Hemophilia.|
- Haemophilia at DMOZ
- Hemophilia.ca, Hemophilia A & B information, Canadian Hemophilia Society
- Raw Living Radio Interviews Dr Robert Cassar as part of a 3 Show Series in HD 2014 from the EarthShiftProject.com an Educational and Informational Research Organization welcoming More participation from fellow Student Researchers, That's You!]
- Hemophilia.org, Types of Bleeding Disorders], UK Haemophilia Society
- Haemophilia.org.uk, An Introduction to Haemophilia, UK Haemophilia Society
- History of Heamophilia Research
- Hemophilia Magazine, National Hemophilia Foundation